| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 15,628 | 15,664 | 17:08 | |
| 15,614 | 15,684 | 17:08 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 15,858 | 1.278 | |||
| 15,840 | 12.700 | |||
| 15,838 | 60 | |||
| 15,776 | 3.200 | |||
| 15,774 | 1.499 | |||
| 15,740 | 3.200 | |||
| 15,708 | 580 | |||
| 15,706 | 2.140 | |||
| 15,704 | 2.140 | |||
| 15,702 | 1.560 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/via.htm [/URL] | ||||
| 270 | 15,668 | |||
| 1.560 | 15,662 | |||
| 2.140 | 15,660 | |||
| 3.200 | 15,614 | |||
| 3.000 | 15,600 | |||
| 580 | 15,598 | |||
| 3.200 | 15,552 | |||
| 100 | 15,550 | |||
| 60 | 15,536 | |||
| 12.700 | 15,520 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 26.810 | 1,058 | 28.357 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 09:04:41 | 15,858 | 190 |
| Tagesumsatz Xetra | +0,274 +1,76 % | 190 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VIATRIS Aktie jetzt für 0€ handeln | |||||
| 17:06 | Viatris gains approval of Gwyn Lo contraceptive patch | - | Seeking Alpha | ||
| 13:30 | Viatris receives FDA approval for low-dose contraceptive patch | 4 | Investing.com | ||
| 12:59 | Viatris Inc.: Viatris Receives U.S. FDA Approval for Gwyn Lo, a Once-Weekly Contraceptive Patch | 310 | PR Newswire | New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option
Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health
... ► Artikel lesen | |
| Fr | Merck signs licensing deals with companies including Viatris for new HIV pill | 22 | Seeking Alpha | ||
| 22.07. | Viatris' Quarterly Earnings Preview: What You Need to Know | 18 | Barchart.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:38 | IGC Pharma, Inc.: IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease... ► Artikel lesen | |
| 14:36 | SciSparc Ltd: SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company | GlobeNewswire (Europe) | TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage... ► Artikel lesen | |
| 14:18 | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Astrazeneca von 18500 auf 20200 Pence angehoben und die Einstufung auf "Outperform" belassen. Mit Blick auf die... ► Artikel lesen | |
| 13:10 | Teva Pharmaceutical Industries Ltd: Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy | GlobeNewswire (Europe) | Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively... ► Artikel lesen | |
| 15:54 | DZ BANK stuft GSK auf 'Halten' | dpa-AFX-Analyser | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für GSK von 2100 auf 2000 Pence gesenkt, aber krdie Einstufung auf "Halten" belassen. Die vorgelegten Quartalszahlen seien nur "Hintergrundmusik"... ► Artikel lesen |